Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $24.5 million.

  • Theravance Biopharma's Change in Acquisitions & Divestments fell 1090.26% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.5 million, marking a year-over-year increase of 1778.13%. This contributed to the annual value of $139.8 million for FY2024, which is 9587.96% up from last year.
  • Latest data reveals that Theravance Biopharma reported Change in Acquisitions & Divestments of $24.5 million as of Q3 2025, which was down 1090.26% from $20.3 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Change in Acquisitions & Divestments registered a high of $115.5 million during Q1 2021, and its lowest value of $8.7 million during Q2 2023.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $40.1 million (2024), whereas its average is $43.1 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first crashed by 7994.91% in 2023, then soared by 22605.63% in 2024.
  • Theravance Biopharma's Change in Acquisitions & Divestments (Quarter) stood at $64.8 million in 2021, then dropped by 23.92% to $49.3 million in 2022, then tumbled by 82.43% to $8.7 million in 2023, then surged by 362.38% to $40.1 million in 2024, then tumbled by 38.83% to $24.5 million in 2025.
  • Its Change in Acquisitions & Divestments was $24.5 million in Q3 2025, compared to $20.3 million in Q2 2025 and $32.6 million in Q1 2025.